“This study shows the promise of MCED tests in detecting cancers very early, and sets the benchmark sensitivities required for their success” said Dr. Bert Vogelstein.
Researchers at Johns Hopkins have developed a blood test capable of detecting cancer up to three years before symptoms appear, offering new hope for early diagnosis.
“This study shows the promise of MCED tests in detecting cancers very early, and sets the benchmark sensitivities required for their success,” said Dr. Bert Vogelstein, senior author and co-director of the Ludwig Center.
The multicancer early detection (MCED) test analyzed blood samples from 52 participants. Half were later diagnosed with cancer. The test identified cancer in 8 of the 26 future patients — and in 4 cases, signs were present over three years before diagnosis.
“Three years earlier provides time for intervention,” said lead researcher Dr. Yuxuan Wang. “The tumors are likely to be much less advanced and more likely to be curable.”
Although not FDA-approved for wide use, experts say MCED tests could complement standard screenings.
“Detecting cancers years before their clinical diagnosis could help provide management with a more favorable outcome,” said Dr. Nickolas Papadopoulos.